The Journal of Immunology, Vol 145, Issue 5 1518-1522, Copyright © 1990 by American Association of Immunologists

ARTICLES

Matrix-bound plasminogen activator inhibitor type 1 inhibits the invasion of human monocytes into interstitial tissue

JC Kirchheimer, BR Binder and HG Remold
Department of Orthopedics, University of Vienna, Austria.

Invasion of tissue by monocytes in the course of cellular immune reactions is a multistep process that is thought to be based on the action of urokinase type plasminogen activator (u-PA), an ubiquitous serine protease able to convert the zymogen plasminogen into the active protease plasmin. Expression and occupation of urokinase-type plasminogen activator receptors (u-PA-R) are known to be up-regulated by IFN-gamma and TNF-alpha, and endogenously occupied u-PA-R were found to be instrumental in monocyte invasiveness. We used the amnion invasion assay to investigate whether monocyte invasiveness is affected by matrix-bound plasminogen activator inhibitors (PAI) and by fluid phase u-PA. We show in this study that preincubation of amnion membranes with 1.5 U/cm2 PAI-1 decreases invasion of IFN-gamma activated monocytes by 70% compared with controls. Anti-vitronectin antibodies, which block PAI-1 binding to the matrix, abrogate the inhibitory effect of PAI-1 on monocyte invasiveness, indicating that active PAI-1 is bound via matrix-associated vitronectin. In contrast, preincubation of the amnion membrane with PAI-2 which does not bind to the extracellular matrix has no effect on monocyte invasiveness. Finally, the inhibitory action of matrix-bound PAI-1 can be abrogated by addition of 5 IU/ml u-PA to the monocytes in the invasion chamber. These findings indicate that monocyte invasiveness might be regulated not only by expression and occupation of u-PA-R but also by matrix- bound PAI-1.

This article has been cited by other articles:

				A. Garcia-Touchard, T. D. Henry, G. Sangiorgi, L. G. Spagnoli, A. Mauriello, C. Conover, and R. S. Schwartz Extracellular Proteases in Atherosclerosis and Restenosis Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1119 - 1127. [Abstract] [Full Text] [PDF]

				B. Degryse, J. G. Neels, R.-P. Czekay, K. Aertgeerts, Y.-i. Kamikubo, and D. J. Loskutoff The Low Density Lipoprotein Receptor-related Protein Is a Motogenic Receptor for Plasminogen Activator Inhibitor-1 J. Biol. Chem., May 21, 2004; 279(21): 22595 - 22604. [Abstract] [Full Text] [PDF]

				M. A. Olman, J. S. Hagood, W. L. Simmons, G. M. Fuller, C. Vinson, and K. E. White Fibrin Fragment Induction of Plasminogen Activator Inhibitor Transcription Is Mediated by Activator Protein-1 Through a Highly Conserved Element Blood, September 15, 1999; 94(6): 2029 - 2038. [Abstract] [Full Text] [PDF]

				T. Syrovets, B. Tippler, M. Rieks, and T. Simmet Plasmin Is a Potent and Specific Chemoattractant for Human Peripheral Monocytes Acting Via a Cyclic Guanosine Monophosphate-Dependent Pathway Blood, June 15, 1997; 89(12): 4574 - 4583. [Abstract] [Full Text] [PDF]

				K. M.F. Khan and D. J. Falcone Role of Laminin in Matrix Induction of Macrophage Urokinase-type Plasminogen Activator and 92-kDa Metalloproteinase Expression J. Biol. Chem., March 28, 1997; 272(13): 8270 - 8275. [Abstract] [Full Text] [PDF]

				R.D. Kenagy, S. Vergel, E. Mattsson, M. Bendeck, M.A. Reidy, and A.W. Clowes The Role of Plasminogen, Plasminogen Activators, and Matrix Metalloproteinases in Primate Arterial Smooth Muscle Cell Migration Arterioscler. Thromb. Vasc. Biol., November 1, 1996; 16(11): 1373 - 1382. [Abstract] [Full Text]